Q3 2026 IQVIA Earnings Conference Call - IQVIA HOLDINGS INC

Explicit Guidance:

• Full Year 2026 Revenue: Raised to $17.35B–$17.50B, implying 6.4%–7.3% YoY growth; assumes ~200–250 bps contribution from acquisitions and ~20 bps tailwind from FX (implying ~70 bps FX headwind in Q4).
• Full Year 2026 Adjusted EBITDA: Raised to $4.025B–$4.055B, implying 6.3%–7.0% YoY growth.
• Full Year 2026 Adjusted Diluted EPS: Raised to $12.90–$13.00, implying 8.2%–9.1% YoY growth.
• Margins: Expects flat Adjusted EBITDA margins year-over-year at ~23.2% (operational improvement offset by pass-through mix and currency).
• Q4 2026 Run-Rate Assumptions (for FY27 modeling):
  • Net interest expense: ~$210M.
  • Depreciation and amortization: ~$160M.
  • Weighted average diluted share count: ~169M.
  • Currency assumptions based on rates as of Oct 26, 2026.
• FY2027 Guidance: Formal detailed guidance for 2027 to be provided in February 2027 alongside FY2026 full-year results; broader framework to be shared at Investor Day on December 1, 2026.

Business-Segment Outlook:

• Clinical (R&D Solutions):
  • Demand indicators encouraging; EBP funding up >85% YoY (YTD $90B, exceeding total last year); clinical trial starts up high single digits.
  • R&D Solutions net new bookings up 14% YoY (12-month LTM: $11.7B), marking five consecutive quarters of growth.
  • Contracted backlog $32.6B; next 12 months from backlog $9.4B (up 10% YoY).
  • Expect continued momentum in full-service bookings as outsourcing trends re-accelerate; long-cycle business benefits from strong pipeline.
• Commercial Solutions:
  • Revenue growth double last year's organic rate; pipelines at record levels.
  • Demand outlook favorable: New drug launches up >40% YoY; decision timelines shortening; approvals up 40% YoY, expected to drive launches within 6–12 months.
  • Q3 seasonal volatility acknowledged; full-year growth expected to remain strong.
• Segment Performance Trends:
  • Win rates improved 2–3 bps; strong execution across Information, Analytics, Consulting, and Patient Engagement sub-segments.
  • 4 consecutive quarters of strong Commercial revenue growth; record backlog levels.

Market and Competitive Outlook:

• Industry Structure: Large pharma re-procurement cycles (12–18 months) have concluded; IQVIA emerged with increased scope and partnerships, while smaller CROs likely lost market share.
• Growth Drivers: Biotech/EVP funding growth (upper single digits) outpacing Large Pharma (low single digits, 2–3%); 17,000 EVPs globally.
• Competitive Positioning: Differentiation driven by proprietary data, context, and AI agents; "agentic solutions" winning deals previously lost or stalled.
• Outsourcing Trends: Outsourcing trend remains intact; pendulum has swung back toward Full Service and FSP models post-re-procurement.

Macro / Industry Outlook:

• Funding Environment: EBP funding at $90B YTD (up 85% YoY), nearly double pre-COVID annual rates; clinical trial starts up high single digits.
• Regulatory/Policy Impact: Previous uncertainty from IRA pricing negotiations, potential MFN tariffs, and inflationary pressures has largely cleared; decision timelines normalizing.
• FX: Assumes $20M tailwind in 2026 guidance; Q4 implies 70 bps headwind based on current rates.
• Economic Context: Market environment improving; demand constraints from prior uncertainty lifting.

Strategic Initiatives:

• AI Deployment:
  • Currently deployed 415 AI agents; "TechIQ" event showcased new capabilities with partners (NVIDIA, Microsoft, AWS, Snowflake, Viva).
  • AI acting as a win-rate differentiator (e.g., optimizing Phase III timelines by 9 months, reducing operational risk).
  • Internal "AI gentrification" and process automation expected to drive ~80 bps operational margin expansion, offsetting external pass-through headwinds.
• M&A/Capabilities: Expanded early-phase engagement capabilities via acquisitions (Discovery, Phase 1) and hiring of ex-SDRs to penetrate EVP market earlier.
• Customer Integration: Deepening trust via agentic platforms for real-time insights, patient sentiment analysis, and automated benefits verification.
• Backlog Management: Completed $2.1B backlog adjustment for trials inactive >18 months to improve visibility; trials may resume and be added back without impacting booking metrics.

Risks and Headwinds to Outlook:

• Currency Volatility: 2026 guidance assumes rates as of Oct 26; Q4 implied headwind suggests potential FX sensitivity.
• Pass-Through Mix: Pass-through revenues creating a ~70 bps gross margin headwind; operational improvement (80 bps) required to maintain net margin.
• Seasonality: Q4 typically presents difficult comparisons due to seasonality; Q3 volatility noted (European summer impact).
• Backlog Adjustment: Removed $2.1B from backlog; if these trials resume, value adds to backlog but not bookings, potentially distorting future growth rates if not tracked carefully.
• Pricing Negotiations: While large pharma re-procurement concluded, specific trial-level negotiations with procurement continue.
• Execution Risks: Dependency on successful AI adoption and integration; potential delays in commercial launch execution.

Management Tone on the Future:

• Confidence: High; describes performance as "outstanding" and "strongest clinical bookings in four years."
• Sentiment: Optimistic about the "improving market environment," citing accelerating organic growth (2x Commercial, 3x Clinical vs. prior year).
• Guidance Changes: Raised full-year guidance for Revenue, EBITDA, and EPS; explicitly states confidence in EBITDA dollar guidance irrespective of pass-through distortions.
• AI Narrative: Views AI not as a trend but as a "new way of doing business" that fundamentally changes client engagement and operational efficiency.
• Strategic Clarity: Confident in long-term growth trajectory driven by EVP expansion and the consolidation of the CRO industry around large, diversified players.

Miscellaneous:

• Investor Day: Scheduled for December 1, 2026; will provide framework for 2027 expectations.
• Segment Reporting: New reporting structure effective Jan 1, 2026; prior periods recast.
• Backlog Clarification: Commercial backlog not tracked due to short-cycle nature (contract-based); focus is on pipeline and win rates.
• Book-to-Bill: RDS book-to-bill ratio was 1.2 in the quarter.
• Free Cash Flow: Strong performance at 120% of adjusted net income in Q3.